share_log

Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder

Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder

武田吹捧Hyqvia治疗罕见神经炎性疾病的令人鼓舞的数据
Benzinga Real-time News ·  2022/07/21 10:36
  • Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) met its primary endpoint. 
  • CIPD is a rare chronic autoimmune disease affecting the peripheral nervous system, resulting in progressive symmetric weakness and impaired sensory function in the arms and legs.
  • Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment. 
  • Also Read: Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years.
  • Analyses from ADVANCE-1 are ongoing, and the company anticipates disclosing additional data in an upcoming medical forum.
  • HYQVIA showed a favorable safety profile in topline analyses, further supporting its use as maintenance therapy for CIDP. 
  • Of the 62 patients treated with HYQVIA, most treatment-related adverse events were reported as mild or moderate. No new safety risks were reported with HYQVIA. 
  • The safety profile of HYQVIA in CIDP will be further supported by data from the ongoing ADVANCE-3 trial, an extension study with up to six years of follow-up data on some participants.
  • Price Action: TAK shares are up 0.52% at $14.56 during the market session on the last check Thursday.
  • 武田制药株式会社Hyqvia维持治疗慢性炎症性脱髓鞘多神经根神经病(CIDP)的(纽约证券交易所市场代码：TAK)3期试验(Advance-1)达到了其主要终点。
  • CIPD是一种罕见的慢性自身免疫性疾病，影响周围神经系统，导致进行性对称性虚弱和手臂和腿部感觉功能受损。
  • TOPLINE数据显示，HyQvia减少了神经肌肉残疾和损伤的复发。
  • 另请阅读： 武田的遗传性血管水肿治疗可防止12岁以下儿童发作.
  • 来自Advance-1的分析正在进行中，该公司预计将在即将到来的医学论坛上披露更多数据。
  • HyQvia在背线分析中显示出良好的安全性，进一步支持将其用作CIDP的维持疗法。
  • 在接受HyQvia治疗的62名患者中，据报道，大多数与治疗相关的不良反应为轻度或中度。没有关于HyQvia的新安全风险的报告。
  • HyQvia在CIDP中的安全性将得到正在进行的Advance-3试验数据的进一步支持，该试验是一项扩展研究，对一些参与者进行了长达6年的随访数据。
  • 价格行动：周四尾盘，德意志银行股价上涨0.52%，至14.56美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发